JPMorgan Chase & Co. Increases Axon Enterprise (NASDAQ:AXON) Price Target to $365.00

Axon Enterprise (NASDAQ:AXON - Free Report) had its target price increased by JPMorgan Chase & Co. from $330.00 to $365.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company's stock.

Several other brokerages have also commented on AXON. Robert W. Baird raised their price objective on Axon Enterprise from $260.00 to $300.00 and gave the company an outperform rating in a research report on Thursday, February 22nd. Morgan Stanley raised their target price on shares of Axon Enterprise from $250.00 to $285.00 and gave the company an equal weight rating in a research note on Wednesday, February 28th. JMP Securities boosted their price target on Axon Enterprise from $250.00 to $285.00 and gave the stock a market outperform rating in a research report on Tuesday, February 6th. The Goldman Sachs Group raised their price objective on Axon Enterprise from $297.00 to $339.00 and gave the company a buy rating in a research report on Wednesday, February 28th. Finally, Barclays boosted their target price on Axon Enterprise from $296.00 to $308.00 and gave the stock an overweight rating in a report on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $312.64.

Axon Enterprise Stock Up 1.8 %

AXON traded up $5.83 on Thursday, hitting $324.09. The company had a trading volume of 704,610 shares, compared to its average volume of 465,133. The stock has a fifty day simple moving average of $296.35 and a 200-day simple moving average of $253.55. The company has a debt-to-equity ratio of 0.42, a current ratio of 3.00 and a quick ratio of 2.66. The firm has a market capitalization of $24.46 billion, a P/E ratio of 140.91 and a beta of 0.93. Axon Enterprise has a 52-week low of $175.37 and a 52-week high of $329.87.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.29. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. The firm had revenue of $432.14 million during the quarter, compared to analyst estimates of $418.97 million. As a group, equities analysts expect that Axon Enterprise will post 2.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

A number of large investors have recently added to or reduced their stakes in AXON. ICA Group Wealth Management LLC purchased a new stake in shares of Axon Enterprise during the 4th quarter valued at about $25,000. Hollencrest Capital Management purchased a new stake in Axon Enterprise during the first quarter valued at approximately $29,000. BKM Wealth Management LLC bought a new position in Axon Enterprise in the fourth quarter worth approximately $32,000. First Capital Advisors Group LLC. purchased a new position in shares of Axon Enterprise during the 2nd quarter worth $33,000. Finally, Tyler Stone Wealth Management purchased a new position in shares of Axon Enterprise during the 2nd quarter worth $35,000. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.